AbbVie NYSE ABBV
$153.93 0.0000 0.0000%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free
Rating Finrange Показатель: 44 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

273.69B
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

340.63B
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.

0.83
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.

1.78B
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.

13.69 %
Upcoming events AbbVie All events
No upcoming events scheduled

Stock chart AbbVie

Stock analysis AbbVie

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.

More
21.93 3.64
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.

More
17.76 1.97
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.

More
12.44 -4.68
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.

More
2.44 0.70
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.

More
76.64 113.88

Price change AbbVie per year

77.49$ 121.53$
Min Max

Summary analysis AbbVie

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure AbbVie

Revenue and net income AbbVie

All parameters
Stock news AbbVie All news

AbbVie Gets FDA Expanded OK of Skyrizi in Crohn's Disease >ABBV

AbbVie Gets FDA Expanded OK of Skyrizi in Crohn's Disease >ABBV

AbbVie Seeks FDA OK for ABBV-951 in Advanced Parkinson's Disease >ABBV

AbbVie Seeks FDA OK for ABBV-951 in Advanced Parkinson's Disease >ABBV

Berkshire Hathaway Exited Bristol Myers and AbbVie Stakes in 1Q

Berkshire Hathaway Exited Bristol Myers and AbbVie Stakes in 1Q

AbbVie: Upadacitinib Achieved Clinical Remission at One Year in Crohn's Disease

AbbVie: Upadacitinib Achieved Clinical Remission at One Year in Crohn's Disease

AbbVie Shares Lower After Revenue Miss

AbbVie Shares Drop Amid Missed Sales Expectations for Key Drugs

AbbVie Shares Lower After Revenue Miss

AbbVie's stock is down 3% after missing on revenue in the first quarter of 2022

Health Canada Approves AbbVie Treatment for Bipolar Disorder, Schizophrenia

Health Canada Approves AbbVie Treatment for Bipolar Disorder, Schizophrenia

Dragonfly Expands Research Collaboration With AbbVie

Dragonfly Expands Research Collaboration With AbbVie

Abbvie Vice Chairman Severino Departs for Flagship Pioneering

Abbvie Vice Chairman Severino Departs for Flagship Pioneering

AbbVie Reports Promising Mid-Stage Trial Data for Blood-Cancer Treatment

AbbVie Reports Promising Mid-Stage Trial Data for Blood-Cancer Treatment

About company AbbVie

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Address:
1 North Waukegan Road, North Chicago, IL, United States, 60064-6400
Company name: AbbVie
Issuer ticker: ABBV
ISIN: US00287Y1091
Country: USA
Exchange: NYSE
Currency: $
IPO date: 2013-01-02
Sector: Healthcare
Industry: Biotechnology
Site: https://www.abbvie.com

On which stock exchange are AbbVie (ABBV) stocks traded?

AbbVie (ABBV) stocks are traded on NYSE.

What is the ticker of AbbVie stocks (ABBV)?

The stock ticker of AbbVie’s stocks or in other words, the code is ABBV. The stocks are currently listed on the NYSE exchange.

In which sector and industry does AbbVie (ABBV) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, AbbVie (ABBV) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are AbbVie (ABBV) stocks traded?

AbbVie (ABBV) stocks are traded on the NYSE exchange in dollars.

What is the price of AbbVie (ABBV) stocks today?

The current price of AbbVie stocks on 07.07.2022 is 153.93 dollars. per share.

What is the dynamics of AbbVie (ABBV) stocks from the beginning of the year?

AbbVie (ABBV) quotes have increased by 0% from the beginning of the year up to 153.93 dollars. per 1 stocks.

How much did AbbVie (ABBV) stocks increase in июле 2022?

This month AbbVie (ABBV) quotes have increased by 0.08% to 153.93 dollars. per share.

How much are AbbVie (ABBV) stocks worth?

Today, on October, 07.07.2022 AbbVie’s (ABBV) stocks cost 153.93 dollars..

What is the market capitalization of AbbVie (ABBV)?

Capitalization is the market value of AbbVie (ABBV) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 07.07.2022, the market capitalization of AbbVie (ABBV) is estimated at about 273687540000 dollars.